Received
A study relating to gastrin release from gastrinoma cells by neuromedin is and C-terminal decapeptide of gastrin releasing peptide (GRP-10) has not yet been reported.
Therefore, we studied the effects of neuromedin B and GRP-10 on gastrin release from cultured dispersed cells prepared from both the primary tumor in the pancreas and the metastatic tumor in the liver from a case of malignant Zollinger-Ellison syndrome. Both the primary and metastatic tumors obtained by a curative operation contained similar concentrations of gastrin and glucagon, whereas the primary tumor contained 10 times more insulin than the metastatic tumor. Gastrin release from cultured cells of both tumors was suppressed by 0.1 and 10nM neuromedin B and tended to be suppressed by 0.1-10nM GRP-10. However, insulin release from cultured cells of the pancreatic tumor was stimulated by GRP-10, but not by neuromedin B. These results might suggest that receptor function for the bombesin family peptides is abnormal in gastrinoma cells in both primary and metastatic tumors, and that a major source of insulin secretary cells is the contaminated normal islet cells in the primary tumor.
Zollinger-Ellison
syndrome is characterized by recurrent peptic ulceration, marked gastric acid hypersecretion and islet cell tumors secreting gastrin (Zollinger and Ellison, 1955; McGuigan and Trudeau, 1969) .
Its incidence is low, particularly in
Japan where only about 100 cases were reported prior to 1982 (Kishimoto and Miyoshi, 1983) . Gastrin release from this tumor is abnormal; it is not suppressed by secretin (Lamers and Van Tongeren, 1977; McGuigan and Wolfe, 1980) , and is weakly stimulated by bombesin (Basso et al., 1981; Jansen and Lamers, 1982) . Neuromedin B and C-terminal decapeptide of gastrin releasing peptide (GRP-10) are mammalian bombesin-like peptides (Mina-mino et al., 1983; Okada et al., 1984; Reeve et al., 1983) which stimulate the release of gastrin, insulin and glucagon in a similar manner to bombesin (Spindel, 1986; Kawai et al., 1988) . However, no study relating to gastrin release from gastrinoma by these peptides has yet been reported. The effects of neuromedin B and GRP-10 on gastrin release from cultured dispersed cells, from both the primary tumor in the pancreas and the metastatic tumor in the liver obtained from a case of malignant Zollinger-Ellison syndrome, are reported. nodule, capsular invasion was prominent, and the tumor cells protruded in the pancreatic duct, obstructing the lumen.
After the operation, her plasma gastrin level fell to 50pg/ml and she was discharged. Materials and Methods
Materials
Neuromedin B and GRP-10 used in this study were synthesized by the solid phase method (Mukai et al., 1987) . They were purified by gel filtration and reverse phase highperformance liquid chromatography described previously (Mukai et al., 1987) , and proved to be at least 98% pure. 
Hormone assay
The gastrin level was determined with a commercial kit (Gastrin-RIA kite, Dainabot Radioisotope, Tokyo, Japan).
The antiserum in this immunoassay is directed against the Cterminal residues of gastrin.
Insulin and glucagon levels were measured by RIAs according to the method of Herbert et al.(1965) , and Faloona and Unger (1974) with E-7 antibody (kindly donated by Dr. H. von Schenck, von Schenck, 1977) , respectively. Neither neuromedin B nor GRP-10 cross-reacted with the immunoassay systems. 
Results
Hormone content of tumors There was 174ng/g (tissue wet weight) gastrin in the primary tumor and 219ng/g in the metastatic tumor. The amount of insulin in the primary tumor was 198ng/g tissue wet weight and that in the metastatic tumor was estimated to be 28ng/g because it was close to the sensitivity limit of the RIA. The amount of giucagon in the primary tumor and the metastatic tumors was 8.6 and 7.3ng/g tissue wet weight, respectively.
Basal
hormone release from cultured tumor cells Table 2 shows the hormone content in the basal medium obtained after 24hrincubation and in the mediums of following incubation twice for 1hr each time. Gastrin and insulin were clearly released from Effects of neuromedin B and GRP-1O on hormone release from cultured tumor cells Gastrin release from both primary and metastatic tumor cells decreased significantly with 0.1nM neuromedin B. 1nM neuromedin B and 10nM neuromedin B also inhibited gastrin release from metastatic tumor cells and from primary tumor cells, respectively. 0.1-10nM GRP-10 tended to inhibit gastrin release from both cultured primary and metastatic tumor cells (Fig. 2) . Insulin release from cultured primary tumor cells was stimulated by 0.1 and 1nM GRP-10 and was not affected by 0.1-10nM neuromedin B. (Fig. 3) . Glucagon release tended to be suppressed by neuromedin B and GRP-10, but the values were too small to make a statistical analysis when the glucagon concentration in the incubation medium itself was subtracted (data not shown). not by neuromedin B. Neuromedin B and GRP-10 are mammalian bombesin-like peptides which stimulate the release of gastrin, insulin and glucagon. The potency of GRP-10 was found to be over 10 times greater than that of F neuromedin B in our previous study (Kawai et al., 1988) . These effects of bombesin-like peptides are considered to be result of their binding to receptor sites. However, in this study gastrin release was suppressed by neuromedin B, which might be ascribed to an abnormality in the function of the receptor for bombesin-like peptides in tumor cells. The absence of the suppression of gastrin release by secretion in this patient and its small increase after the ingestion of a mixed meal (Table 1) suggest a similar abnormality.
Discussion
The abnormal regulation of hormone release in endocrine tumors is sometimes obserbed, i. e.; no stimulation of insulin release by glucose in insulinoma, no suppression of growth hormone release by glucose and an abnormal stimulation of it by TRH in acromegaly, although the precise mechanisms of these abnormalities has not yet been understood.
However, the response of insulin release from cultured cells to GRP-10 was normal. The amount of insulin in tumors was about 100 times lower than that in the normal pancreas, and the amount in the metastatic tumor in the liver was about 15% that in the primary tumor in the pancreas. These results suggest that the majority of insulin from the tumor in the pancreas is derived from contaminated islet cells as shown in Fig. 1-B , although the tumor was well defined from a normal pancreas.
The amount of glucagon in the primary tumor was also slightly higher than that in the metastatic tumor.
Previous in vivo studies of gastrinoma demonstrated that the plasma gastrin level of patients increased little in response to an intravenous infusion of bombesin, compared with patients with hypergastrinemia of antral origin (Basso et al., 1981 and Jansen and Lamers 1982) . Gastrin release was not clearly stimulate by the infusion of bombesin in 4 patients out of 8 with a non-operated gastrinoma (Jansen and Lamers, 1982) , or in 2 patients out of 16 with Zollinger-Ellison syndrome (Basso et al., 1981) . In addition, the response seems to be weak in patients with liver metastases (Basso et al., 1981) .
Since the effects of bombesin-like peptides on gastrointestinal and pancreatic hormone release are thought to be similar, the suppression of gastrin release by neuromedin B in this in vitro study is somewhat different from previous in vivo studies, suggesting poor response of gastrinoma cells to bombesin. Although the data presented are these for only one malignant gastrinoma, it is suggested that neuromedin B might suppress gastrin release from a maglinant gastrinoma taking into account of the abnormal response to bombesin in patients with malignant gastrinoma (Basso et al., 1981) . Therefore, it is possible that the infusion of neuromedin B may be useful in distinguishing between malignant and benign gastrinoma. In this patient, we have not examined the response of the plasma gastrin level to neuromedin B or GRP-10, because the use of these peptides was limited to animals in this study.
